Mona Shahriari, MD, an Assistant Clinical Professor of Dermatology at Yale University School of Medicine in New Haven, CT, and the Associate Director of Clinical Trials at Central Connecticut Dermatology (CCD) Research, shares her updated monitoring protocols for patients on biologics, Janus kinase (JAK), and Tyrosine Kinase 2 (TYK2) inhibitors. Dr. Shahriari gave a talk on this topic at the 2025 Diversity in Dermatology Meeting in Louisville, KY.
